

Curriculum Vitae

*** Within 3 pages**

	Name in Full	Yong Joon Lee, M.D., Ph.D.
	Country	Republic of Korea
	Affiliation	Assistant Professor, Department of Surgery CHA Bundang Medical Center, CHA University School of Medicine
	Email	joonjoonlee@gmail.com

Educational Background

2006.03 - 2012.02 M.D., Yonsei University College of Medicine, Republic of Korea
 2017.03 - 2022.02 Integrated M.S. & Ph.D., Graduate School of Medical Science and Engineering,
 Korea Advanced Institute of Science and Technology (KAIST), Republic of Korea

Professional Career

2012.02 - 2013.02 Internship, Severance Hospital, Yonsei University College of Medicine
 2013.03 - 2017.02 Residency, Department of Surgery, Severance Hospital, Yonsei University College of Medicine
 2022.03 - 2023.02 Fellow, Department of Surgery, Severance Hospital, Yonsei University College of Medicine
 2023.03 - 2024.02 Clinical Assistant Professor, Department of Surgery, Severance Hospital, Yonsei University College of Medicine
 2024.03 - Present Assistant Professor, Department of Surgery, CHA Bundang Medical Center, CHA University School of Medicine

Research Field

Colorectal surgery and surgical oncology; colorectal cancer immunology; tumor microenvironment and T-cell biology; single-cell and spatial multi-omics; translational cancer immunotherapy; TIL- and TCR-based cellular immunotherapy.



1. Lee YJ, et al. Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. *Cell Reports Medicine*. 2025;6(10):102360.
2. Lee YJ, et al. CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. *Science Immunology*. 2022;7(74):eabn8390.
3. Jeon SH, Lee YJ, et al. Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma. *Cancer Immunology, Immunotherapy*. 2022.
4. Lee YJ, et al. Temporal changes in immune cell composition and cytokines in response to chemoradiation in rectal cancer. *Scientific Reports*. 2018;8:7565.
5. Lee YJ, et al. Prognostic Impact of Immunonutritional Status Changes During Preoperative Chemoradiation in Patients With Rectal Cancer. *Annals of Coloproctology*. 2016;32(6):208-214.
6. Kim HD, et al. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. *Hepatology*. 2020;71(3):955-971.
7. Kim JH, et al. Functions of human liver CD69+CD103-CD8+ T cells depend on HIF-2 α activity in healthy and pathologic livers. *Journal of Hepatology*. 2020;72(6):1170-1181.
8. Kim HD, et al. Implication of CD69+CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma. *Liver International*. 2021;41(4):764-776.
9. Leem G, et al. Tumour-infiltrating bystander CD8+ T cells activated by IL-15 contribute to tumour control in non-small cell lung cancer. *Thorax*. 2022;77(8):769-780.
10. Park B, et al. HLA-I-restricted CD8+ T cell immunity may accelerate tumorigenesis in conjunction with VHL inactivation. *iScience*. 2022;25(6):104467.
11. Chuah S, et al. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. *Journal of Hepatology*. 2022;77(3):683-694.

Selected Awards / Presentations

- | | |
|------|--|
| 2026 | 52nd Annual Meeting of Korean Cancer Association - Merit Award |
| 2022 | International Colorectal Research Summit 2022 - Excellence Oral Presentation |
| 2021 | FIMSA 2021 - Poster Presentation Award |
| 2019 | Immunology 2019 (AAI) - Travel Award |

